^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR G724S |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Afatinib as a Potential Therapeutic Option for Non-small Cell Lung Cancer Patients with EGFR G724S
Published date:
01/12/2021
Excerpt:
...all the five patients who acquired G724S at osimertinib progression had baseline EGFR exon 19delins. All of these 8 patients achieved stable disease, resulting in a disease control rate (DCR) of 100% with a median PFS of 4.5 months...afatinib monotherapy could be a potential therapeutic option for NSCLC patients with EGFR G724S.
Source:
Title:
Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
Published date:
08/12/2022
Excerpt:
A patient diagnosed with advanced EGFR-mutated (exon 19 deletion) NSCLC after several lines of treatment – gefitinib, osimertinib, heat shock protein inhibitors and chemotherapy-developed EGFR G724S mutation retaining the exon 19 deletion. She was then treated successfully with afatinib leading to a progression free survival of 9 months (and counting)...we report for the first time the activity of afatinib against EGFR exon 18 G724S mutation in this setting.
DOI:
10.1097/CAD.0000000000001321
Source:
Title:
Successful treatment of Afatinib reversing EGFR Ex19Del/G724S resistance guided by protein-drug docking
Published date:
08/15/2021
Excerpt:
A patient with stage IV adenocarcinoma was found to have Ex19Del/G724S mutation. Treated with Afatinib, he received a progression-free survival(PFS) of more than 1 year.
DOI:
10.1002/onco.13932
